{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:56:56Z","timestamp":1782331016171,"version":"3.54.5"},"reference-count":70,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>von Willebrand disease (VWD) is the most common bleeding disorder and especially milder type 1 VWD might not be cared for in specialty clinics. VW factor levels rise with age, but the rise of these levels does not necessarily correlate with bleeding risk. A recent bleeding history combined with recent labs are important for hemostatic management decision during surgical interventions. Antifibrinolytics appear safe in the population of older adults, whereas desmopressin (DDAVP) should be used cautiously. Where needed, factor concentrates present a great treatment option. Acquired von Willebrand syndrome is vastly underrecognized, but likely to surface in the aging, especially in the setting of comorbidities, such as plasma-cell dyscrasias. Intravenous immunoglobulin can be an effective treatment in this scenario, but potentially increases thrombotic risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2022018534","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:03:25Z","timestamp":1694034205000},"page":"197-204","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["How I treat von Willebrand disorders in older adults"],"prefix":"10.1182","volume":"143","author":[{"given":"Jacqueline N.","family":"Poston","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT"},{"name":"2Division of Clinical Pathology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-5240","authenticated-orcid":false,"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[{"name":"3Washington Center for Bleeding Disorders, Seattle, WA"},{"name":"4Division of Hematology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2024011816211225100_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","article-title":"Prevalence of von Willebrand disease in children: a multiethnic study","volume":"123","author":"Werner","year":"1993","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"2024011816211225100_bib2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand's disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"3","key":"2024011816211225100_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/hae.14263","article-title":"Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States","volume":"27","author":"Michael Soucie","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2024011816211225100_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0037-1619606","article-title":"Acquired von Willebrand syndrome 2004: International Registry--diagnosis and management from online to bedside","volume":"24","author":"Federici","year":"2004","journal-title":"Hamostaseologie"},{"issue":"2","key":"2024011816211225100_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0038-1657877","article-title":"Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause","volume":"54","author":"Balleisen","year":"1985","journal-title":"Thromb Haemost"},{"issue":"6","key":"2024011816211225100_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0034-1384631","article-title":"Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review","volume":"40","author":"Favaloro","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2024011816211225100_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.mbc.0000187250.32630.56","article-title":"Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors","volume":"16","author":"Favaloro","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"2024011816211225100_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/01.ATV.19.8.2012","article-title":"Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension","volume":"19","author":"Ari\u00ebns","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"2024011816211225100_bib9","first-page":"4190","article-title":"Age-associated increase in thrombogenicity and its correlation with von Willebrand factor","volume":"10","author":"Alavi","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"2024011816211225100_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"Alb\u00e1nez","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024011816211225100_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/bloodadvances.2021005430","article-title":"von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis","volume":"6","author":"Kalot","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"2024011816211225100_bib12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJM198710153171604","article-title":"Absence of thrombosis in subjects with heterozygous protein C deficiency","volume":"317","author":"Miletich","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024011816211225100_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood.V69.2.692.692","article-title":"Oral contraceptives and gender affect protein S status","volume":"69","author":"Boerger","year":"1987","journal-title":"Blood"},{"issue":"2","key":"2024011816211225100_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.1998.00800.x","article-title":"Associations of protein C and protein S with serum lipid concentrations","volume":"102","author":"MacCallum","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"2024011816211225100_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cardiores.2004.11.013","article-title":"Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly","volume":"66","author":"Yamamoto","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"6","key":"2024011816211225100_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1055\/s-0034-1384630","article-title":"A\u00a0review of the value of D-dimer testing for prediction of recurrent venous thromboembolism with increasing age","volume":"40","author":"Lippi","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2024011816211225100_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annepidem.2005.06.052","article-title":"Platelet counts differ by sex, ethnicity, and age in the United States","volume":"16","author":"Segal","year":"2006","journal-title":"Ann Epidemiol"},{"key":"2024011816211225100_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fcvm.2019.00109","article-title":"Platelet function in aging","volume":"6","author":"Le Blanc","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2024011816211225100_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"11","key":"2024011816211225100_bib20","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.3324\/haematol.2017.168013","article-title":"Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?","volume":"102","author":"Borghi","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2024011816211225100_bib21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024011816211225100_bib22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A\u00a0quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024011816211225100_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"20","key":"2024011816211225100_bib24","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"8639","key":"2024011816211225100_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(89)92161-2","article-title":"Desmopressin and myocardial infarction","volume":"333","author":"O'Brien","year":"1989","journal-title":"Lancet"},{"issue":"8643","key":"2024011816211225100_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(89)92881-X","article-title":"Desmopressin and myocardial infarction","volume":"1","author":"Lowe","year":"1989","journal-title":"Lancet"},{"issue":"2","key":"2024011816211225100_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJM198801143180215","article-title":"Myocardial infarction in a patient with hemophilia treated with DDAVP","volume":"318","author":"Bond","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024011816211225100_bib28","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/CCM.0000000000004021","article-title":"Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage","volume":"47","author":"Feldman","year":"2019","journal-title":"Crit Care Med"},{"issue":"6","key":"2024011816211225100_bib29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/08850666211031494","article-title":"The safety and efficacy of desmopressin in patients with intracranial hemorrhage and a history of alcohol use","volume":"37","author":"Gunther","year":"2022","journal-title":"J\u00a0Intensive Care Med"},{"issue":"10116","key":"2024011816211225100_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(17)32455-8","article-title":"Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients","volume":"391","author":"Gayet-Ageron","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"2024011816211225100_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1302\/0301-620X.103B3.BJJ-2020-1288.R1","article-title":"Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial","volume":"103-b","author":"Nikolaou","year":"2021","journal-title":"Bone Joint J"},{"issue":"20","key":"2024011816211225100_bib32","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2106\/JBJS.21.00172","article-title":"Tranexamic acid was not associated with increased complications in high-risk patients with hip fracture undergoing arthroplasty","volume":"103","author":"Porter","year":"2021","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"1","key":"2024011816211225100_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/ALN.0000000000003772","article-title":"Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients","volume":"135","author":"Poeran","year":"2021","journal-title":"Anesthesiology"},{"issue":"2","key":"2024011816211225100_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024011816211225100_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2019.05.003","article-title":"Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis","volume":"179","author":"Chornenki","year":"2019","journal-title":"Thromb Res"},{"issue":"11","key":"2024011816211225100_bib36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024011816211225100_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"2024011816211225100_bib38","unstructured":"Alphanate\n          . Properties of treatment options for von Willebrand disease (VWD). Accessed 2 October 2023. https:\/\/www.alphanate.com\/documents\/729928\/730168\/Alphanate+Product+Properties+Chart+Patient.pdf\/490e3dcd-c54b-4a08-80ac-b00cf69ddc7d?t=15145388630002017."},{"key":"2024011816211225100_bib39","unstructured":"Alphanate\n          . Prescribing information. Grifols. Accessed 2 October 2023. https:\/\/www.alphanate.com\/documents\/729928\/730168\/Alphanate+PI_3057619_8.5x11_22668_Secured.pdf\/3e2c7c1d-62f7-66c4-e98b-f00391adf708?t=16399954777782021."},{"key":"2024011816211225100_bib40","unstructured":"CSL Behring\n          . Dosing overview. Accessed 2 October 2023. https:\/\/www.humate-p.com\/hcp\/about-humate-p\/dosing#:\u223c:text=VWF%3ARCo%20and%20FVIII%20content,raising%20FVIII%20to%20supernormal%20levels."},{"key":"2024011816211225100_bib41","author":"Humate-P","year":"2020"},{"key":"2024011816211225100_bib42","author":"Wilate","year":"2020"},{"key":"2024011816211225100_bib43","unstructured":"Baxalta\n          . Prescribing information. Accessed 2 October 2023. https:\/\/www.fda.gov\/media\/94863\/download."},{"issue":"1","key":"2024011816211225100_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024011816211225100_bib45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1365-2516.2008.01785.x","article-title":"Factor V deficiency: a concise review","volume":"14","author":"Huang","year":"2008","journal-title":"Haemophilia"},{"issue":"6","key":"2024011816211225100_bib46","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2024011816211225100_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MBC.0000000000000953","article-title":"Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage","volume":"31","author":"Chuliber","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2024011816211225100_bib48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5482\/HAMO-13-08-0046","article-title":"Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms","volume":"34","author":"Biswas","year":"2014","journal-title":"Hamostaseologie"},{"issue":"1","key":"2024011816211225100_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.08.002","article-title":"Autoimmune acquired factor XIII deficiency due to anti-factor XIII\/13 antibodies: a summary of 93 patients","volume":"31","author":"Ichinose","year":"2017","journal-title":"Blood Rev"},{"issue":"11","key":"2024011816211225100_bib50","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.3324\/haematol.11837","article-title":"Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain","volume":"92","author":"Dear","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"2024011816211225100_bib51","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1097-0142(197106)27:6<1313::AID-CNCR2820270606>3.0.CO;2-W","article-title":"Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment","volume":"27","author":"Gralnick","year":"1971","journal-title":"Cancer"},{"issue":"2","key":"2024011816211225100_bib52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2141.2000.02183.x","article-title":"Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis","volume":"110","author":"Mumford","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"2024011816211225100_bib53","first-page":"345","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024011816211225100_bib54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5551\/jat.RV17031","article-title":"Acquired von Willebrand syndrome associated with cardiovascular diseases","volume":"26","author":"Horiuchi","year":"2019","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"4","key":"2024011816211225100_bib55","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0887-7963(03)00037-3","article-title":"Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome","volume":"17","author":"Warkentin","year":"2003","journal-title":"Transfus Med Rev"},{"issue":"8","key":"2024011816211225100_bib56","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2024011816211225100_bib57","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/hae.13374","article-title":"A\u00a0role for intravenous immunoglobulin in the treatment of acquired von Willebrand syndrome associated with IgM gammopathy","volume":"24","author":"Lavin","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"2024011816211225100_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/hae.12701","article-title":"Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature","volume":"21","author":"Engelen","year":"2015","journal-title":"Haemophilia"},{"issue":"12","key":"2024011816211225100_bib59","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00277-022-04991-9","article-title":"Successful use of lenalidomide to treat refractory acquired von Willebrand disease\u00a0associated with monoclonal gammopathy","volume":"101","author":"Green","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"2024011816211225100_bib60","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2141.2008.07538.x","article-title":"Is rituximab effective in acquired von Willebrand syndrome?","volume":"144","author":"Mazoyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2024011816211225100_bib61","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/flgastro-2018-101116","article-title":"Rituximab to the rescue: novel therapy for chronic gastrointestinal bleeding due to angiodysplasia and acquired von Willebrand syndrome","volume":"10","author":"Hawken","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"6","key":"2024011816211225100_bib62","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"2024011816211225100_bib63","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"issue":"8","key":"2024011816211225100_bib64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2022-328881","article-title":"IVIg-exposure and thromboembolic event risk: findings from the UK Biobank","volume":"93","author":"Kapoor","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"2024011816211225100_bib65","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"2024011816211225100_bib66","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/j.1537-2995.2012.03868.x","article-title":"Immunoglobulin therapy and thrombosis: coincidence or causation?","volume":"52","author":"Drelich","year":"2012","journal-title":"Transfusion"},{"issue":"10","key":"2024011816211225100_bib67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024011816211225100_bib68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11592740-000000000-00000","article-title":"Special considerations with the use of intravenous immunoglobulin in older persons","volume":"28","author":"Cheng","year":"2011","journal-title":"Drugs Aging"},{"issue":"11","key":"2024011816211225100_bib69","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jth.13142","article-title":"Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register","volume":"13","author":"Seaman","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3-4","key":"2024011816211225100_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hemonc.2013.08.004","article-title":"Treating symptomatic coronary artery disease in patients with von Willebrand disease","volume":"6","author":"Hassan","year":"2013","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/3\/197\/2181708\/blood_bld-2022-018534-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/3\/197\/2181708\/blood_bld-2022-018534-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:21:38Z","timestamp":1705594898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/3\/197\/497769\/How-I-treat-von-Willebrand-disorders-in-older"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018534","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}